跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
prostate cancer program
首页
药物
prostate cancer program
prostate cancer program
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
MYC PROGRAM AS A MARKER OF RESPONSE TO ENZALUTAMIDE IN PROSTATE CANCER
申请人: RUTGERS THE STATE UNIV OF NEW JERSEY
优先权: 2023
US
Risk scores based on human phosphodiesterase 4D variant 7 expression
申请人: KONINKLIJKE PHILIPS NV
优先权: 2015
US
Method for treatment of castration-resistant prostate cancer
申请人: UNIV BRITISH COLUMBIA
优先权: 2014
US
2 件公开
Lead compound for targeted human FKBP51 protein and screening method and application thereof
申请人: UNIV LANZHOU
优先权: 2016
CN
Humanized hexokinase 2 small-molecule inhibitor and application thereof
申请人: UNIV LANZHOU
优先权: 2019
CN
Hybridoma producing anti-t-PSA monoclonal antibody, and preparation method of t-PSA detection kit
申请人: DAQING MABCOM BIOLOG TECHNOLOGY CO LTD
优先权: 2012
CN
药物
反馈